NCT06761911 is a Phase 4 clinical trial of Brentuximab Vedotin (Bv) in Hodgkin Lymphoma (Category), sponsored by Xiuhua Sun.

Who is sponsoring NCT06761911?

NCT06761911 is sponsored by Xiuhua Sun.

What drugs are being tested in NCT06761911?

Interventions in NCT06761911: Brentuximab Vedotin (Bv), Sintilimab, Tislelizumab, Bendamustine.

What condition does NCT06761911 study?

NCT06761911 studies Hodgkin Lymphoma (Category).

Is NCT06761911 still recruiting?

NCT06761911 is currently not yet recruiting. Last updated 7 January 2025.

Last reviewed 2025-01-07 · How we verify

NCT06761911

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Not yet recruiting Phase 4 Last updated 7 January 2025

What this trial tests

Phase 4 trial testing Brentuximab Vedotin (Bv) in Hodgkin Lymphoma (Category) in 100 participants. Not yet recruiting.

Timeline

31 December 2024

Primary endpoint
17 December 2025

31 January 2026

Quick facts

Lead sponsor	Xiuhua Sun
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	31 December 2024
Primary completion	17 December 2025
Estimated completion	31 January 2026

Drugs / interventions tested

Brentuximab Vedotin (Bv) — full drug profile →
Sintilimab — full drug profile →
Tislelizumab (TISLELIZUMAB) — full drug profile →
Bendamustine (BENDAMUSTINE) — full drug profile →

Conditions studied

Hodgkin Lymphoma (Category) — all drugs for Hodgkin Lymphoma (Category) →

Sponsor

Xiuhua Sun

Who can join

18 and older, any sex, with Hodgkin Lymphoma (Category). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are: To evaluate the efficacy and toxicity of BV-containing regimen in relapsed/refractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Brentuximab Vedotin (Bv)

Trials testing the same drug.

NCT07178457 — Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance · Phase 3 · not yet recruiting
NCT03540849 — BV After Allogeneic Hematopoietic Stem Cell Transplantation · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06761911 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiuhua Sun
Last refreshed: 7 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06761911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing